Loading...
•
Sep 30, 2021
Tenaya Therapeutics Q3 2021 Earnings Report
Tenaya Therapeutics' third quarter results reflected progress in pipeline programs and operations, marked by the initiation of a global natural history study for pediatric patients with MYBPC3 mutations and cGMP manufacturing for TYA-11631.
Key Takeaways
Tenaya Therapeutics reported its third quarter 2021 financial results, highlighting the initiation of a global natural history study for pediatric patients with MYBPC3 mutations to support clinical development of TN-201 gene therapy, and the initiation of cGMP manufacturing to support the IND filing for TYA-11631 small molecule for HFpEF.
Initiated global natural history study for pediatric patients with MYBPC3 mutation to support clinical development of TN-201 gene therapy.
Presented preclinical data supporting both TN-201 and PKP2 gene therapy programs at the European Society of Gene and Cell Therapy conference demonstrating significant and durable disease reversal and survival in severe murine models of disease.
Initiated cGMP manufacturing to support the IND filing for TYA-11631 small molecule for HFpEF.
Cash, cash equivalents and investments in marketable securities totaled $280.5 million as of September 30, 2021.
Tenaya Therapeutics
Tenaya Therapeutics
Forward Guidance
Tenaya expects its current cash, cash equivalents and investments in marketable securities will be sufficient to fund its current operating plan at least into the second half of 2023.